Swedbank AB Raises Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Swedbank AB lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 77.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,892 shares of the medical equipment provider’s stock after purchasing an additional 16,128 shares during the period. Swedbank AB’s holdings in Zimmer Biomet were worth $3,365,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after purchasing an additional 166,763 shares in the last quarter. Dodge & Cox increased its stake in shares of Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after purchasing an additional 446,018 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Zimmer Biomet by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock worth $233,009,000 after acquiring an additional 58,060 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Down 0.2%

NYSE ZBH opened at $100.03 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The company’s 50 day simple moving average is $100.06 and its 200 day simple moving average is $99.35. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The company has a market capitalization of $19.82 billion, a P/E ratio of 24.34, a PEG ratio of 2.30 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZBH. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday. Evercore ISI decreased their target price on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 8th. Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Finally, Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a research report on Thursday. They set a “buy” rating and a $130.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Moderate Buy” and a consensus target price of $113.16.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.70% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.